a new direction in
endometriosis treatment!
From Women to Women!
Sur180 Therapeutics is a women-centered biotech startup built on 20+ years of translational research by internationally recognized scientists in neuroscience, gastroenterology, and molecular biology. ​​
Flagship Program:
Transforming endometriosis care with non-hormonal, evidence-based therapeutics that address the root causes, not just the symptoms.
​
Grants & Patents:
-
Sur180 Therapeutics has secured a competitive, peer-reviewed grant from the National Institutes of Health (NIH) to advance its novel therapeutic approach for endometriosis.​
​​
-
Sur180 Therapeutics’ intellectual property portfolio includes a granted U.S. patent with exclusive licensing rights and a second patent application under joint ownership.
Why Sur180?
Our name tells our story. Sur, meaning “south” in Spanish, recognizes the roots of our founding team and our base in South Texas and Puerto Rico. 180 speaks to our philosophy: real progress requires turning in a new direction. At Sur180, we are doing exactly that—developing innovative therapies for endometriosis that challenge current treatment paradigms.
The Unmet Need:
Endometriosis Care Is Failing Millions of Women
-
Affects 1 in 10 women of reproductive age.
-
An estimated 190 million globally and 6.5 million in the U.S.
-
Endometriosis remains underdiagnosed and undertreated, with an average delay of 7–10 years from symptom onset to diagnosis.
Our Vision
A New Direction in Endometriosis Treatment
Sur180 Therapeutics is pioneering a new direction in endometriosis care by targeting the hypothalamic-pituitary-adrenal (HPA) axis—also known as the stress system—rather than the traditional gonadal axis.
The Potential of "Drug P"
The principal drug candidate, a safe CRHR1 antagonist previously tested in clinical trials, offers a unique repositioning opportunity for endometriosis. Although it did not advance in mood and addiction disorders due to limitations in those disease models- not safety concerns- it has strong biological rationale for effectiveness in endometriosis, where CRHR1 receptors play a documented role in pain and lesion biology.
​
With its composition-of-matter patent expired, Sur180 Therapeutics can repurpose the molecule without licensing fees and holds a provisional patent covering its novel gynecologic use.
Because endometriotic lesions and pain pathways express high levels of CRH and its receptors, Sur180’s approach uses safe, previously developed small-molecule CRHR1 antagonists to block this stress-response pathway.
